IMbrave150: Atezolizumab plus Bevacizumab in HCC: Efficacy Data and Clinical Practice Implications : Episode 2
IMbrave 150: Patient Characteristics
The panel analyzes how patient characteristics from the IMbrave 150 trial compare to those in other hepatocellular carcinoma studies.
Video content above is prompted by the following:
- How do the patient characteristics from IMbrave 150 compare to other trials that are being studied in HCC?
Recent Videos
Related Content
